At least 20% donor myeloid chimerism is necessary to reverse the sickle phenotype after allogeneic HSCT

Novel curative therapies using genetic transfer of normal globin-producing genes into autologous hematopoietic stem cells (HSCs) are in clinical trials for patients with sickle cell disease (SCD). The percentage of transferred globin necessary to cure SCD is currently not known. In the setting of al...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Blood
Egile Nagusiak: Fitzhugh, Courtney D., Cordes, Stefan, Taylor, Tiffani, Coles, Wynona, Roskom, Katherine, Link, Mary, Hsieh, Matthew M., Tisdale, John F.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Hematology 2017
Gaiak:
Transplantation
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5659067/
https://ncbi.nlm.nih.gov/pubmed/28887325
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-03-772392
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak